Search clinical trials for: Severe hepatic impairment

Total 18598 results

Bristol-Myers Squibb

Not yet recruiting

Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

Hepatic Impairment | Healthy Participants
Bristol-Myers Squibb

Recruiting

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

Healthy Volunteers | Hepatic Impairment

United States
AstraZeneca

Recruiting

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

Hepatic Impairment

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

Healthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

Hepatic Insufficiency | Neoplasms

Spain, United States, Germany, Argentina, Colombia, Greece
Epizyme, Inc.
Sponsor GmbH

Recruiting

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Hepatic Impairment | Advanced Malignant Solid Tumor

France, Belgium, United States, Poland, Slovakia
Janssen Research & Development, LLC

Recruiting

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Amgen

Completed

Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment

Hepatic Impairment

United States
SK Life Science, Inc.

Completed

Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment

Hepatic Impairment

Poland, Slovakia
AstraZeneca

Completed

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Hepatic Impairment

United States, Bulgaria, Slovakia
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Sanofi

Completed

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

Hepatic Function Abnormal

United States, Germany
Reata, a wholly owned subsidiary of Biogen

Completed

Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function

Healthy | Hepatic Impairment

United States
Bausch Health Americas, Inc.

Terminated

Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Hepatic Encephalopathy

United States
Sagimet Biosciences Inc.

Completed

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Cirrhosis | Hepatic Impairment | Non-alcoholic Steatohepatitis

United States, Hungary
Bausch Health Americas, Inc.

Terminated

Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

Severe Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States
Mirati Therapeutics Inc.

Completed

A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Hepatic Impairment

United States
Mitsubishi Tanabe Pharma Corporation

Completed

PK Study in Subjects With Severe Hepatic Impairment (MCI-186-E05 HP)

Healthy | Severe Hepatic Impairment

Czechia, Hungary, Slovakia
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
EQRx International, Inc.

Completed

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Severe Hepatic Impairment

United States
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment

Healthy Volunteers | Hepatic Impairment

United States
AbbVie

Terminated

A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Sunshine Lake Pharma Co., Ltd.

Completed

To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects

Hepatic Impairment

China
Genfit

Completed

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Liver Diseases | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

Moderate Liver Impairment | Severe Liver Impairment

United States
Acerta Pharma BV
AstraZeneca

Completed

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Hepatic Insufficiency | Healthy Subjects | Hepatic Impairment

United States
Radboud University Medical Center
University Medical Center Groningen; Erasmus Medical Center; Leiden University...

Withdrawn

Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls. (POLO)

Hepatic Impairment | HIV-1-infection
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

Hepatic Insufficiency

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects

Hepatic Impairment

Germany, Russian Federation
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDE225..

Normal Hepatic Function | Impaired Hepatic Function

Belgium, Germany, Israel, Bulgaria, United States
Novartis Pharmaceuticals

Completed

Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

Non-alcoholic Fatty Liver Disease

United States
Gilead Sciences

Completed

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

Hepatitis B Virus

United States, Germany, New Zealand
Pfizer

Completed

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Severe Hepatic Impairment

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Hepatic Impairment

United States
Celgene

Completed

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

Healthy Volunteers | Hepatic Impairment

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Hepatic Impairment

Switzerland
Gilead Sciences

Completed

Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

HCV Infection

United States, Germany, New Zealand
Genentech, Inc.

Completed

A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants

Hepatic Insufficiency

United States
Ipsen

Completed

Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects

Hepatic Impairment

Moldova, Republic of, Romania
Lexicon Pharmaceuticals

Completed

Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

Hepatic Impairment

United States
Hoffmann-La Roche

Completed

A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants

Neoplasms

United Kingdom, Israel, United States, Russian Federation, Australia, Greece, Turkey
Allergan

Completed

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

Hepatic Impairment

United States
Novo Nordisk A/S

Completed

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Diabetes Mellitus, Type 2 | Diabetes | Hepatic Impaired

Poland, Slovakia
GlaxoSmithKline

Completed

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States, Australia, New Zealand
GlaxoSmithKline

Completed

A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.

Asthma

Czechia, Slovakia
Takeda

Completed

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Severe Hepatic Impairment

United States

3

Subscribe